SCHEMBL4429609

SCHEMBL4429609

CCOC(=O)c1ccc(C(c2cccs2)c2cccs2)s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.47
HDAC4 P56524 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
HPGD P15428 9/20 0.45
KDM4E B2RXH2 6/20 0.45
ALDH1A1 P00352 6/20 0.45
HSD17B10 Q99714 5/20 0.44
NPSR1 Q6W5P4 4/20 0.44
MAPT P10636 4/20 0.44
TDP1 Q9NUW8 4/20 0.44
CASP1 P29466 3/20 0.44
MAPK1 P28482 3/20 0.44
TSHR P16473 2/20 0.44
CASP7 P55210 2/20 0.44
BAP1 Q92560 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
RAB9A P51151 5/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
NPC1 O15118 4/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4433269 0.80 HDAC3 (0.49) HDAC3HDAC4HDAC1HDAC6HPGD
SCHEMBL14328431 0.77 HDAC3 (0.55) HDAC3HDAC4HDAC1HDAC6HPGD
SCHEMBL4429555 0.77 DAO (0.53) HPGDKDM4EALDH1A1MAPTL3MBTL1
SCHEMBL4438064 0.77 HDAC3 (0.49) HDAC3HDAC4HDAC1HDAC6HPGD
SCHEMBL15573915 0.76 HDAC3 (0.58) HDAC3HDAC4HDAC1HDAC6HPGD
SCHEMBL3330692 0.76 HDAC3 (0.54) HDAC3HDAC4HDAC1HDAC6HPGD
SCHEMBL987399 0.76 HDAC3 (0.54) HDAC3HDAC4HDAC1HDAC6HPGD
SCHEMBL4437519 0.76 CASP1 (0.47) HDAC3HDAC4HDAC1HDAC6HPGD
SCHEMBL422787 0.75 RAB9A (0.62) HPGDKDM4EALDH1A1HSD17B10NPSR1
SCHEMBL4433839 0.75 HDAC3 (0.47) HDAC3HDAC4HDAC1HDAC6HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2125739-A1 MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. (US) 2009-12-02 EP disclosed
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof ENCYSIVE PHARMACEUTICALS, INC. 2008-08-07 US disclosed
WO-2008079371-A1 MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. (US) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof C3AR1, C5, C5AR1 HDAC3 3625/4885HDAC4 4521/4885HDAC1 4373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.